University of Alberta
Metabolomic Technologies is developing advanced metabolomic-based diagnostic tests for management of chronic disease or high value diagnostics. Metabolomics refers to the systematic identification and quantification of the small molecule metabolic products (the metabolome) of a biological system.
The company’s lead product, PolypDxTM, is a highly sensitive diagnostic for early stage detection of colorectal cancer. It is the first and only urine-based test with a high sensitivity for detecting adenomatous polyps, the precursor to colorectal cancer.